Characterizing acute HIV infection in high-risk individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a cohort of individuals with acute HIV infection, focusing on their clinical, immunological, and virological characteristics. It will assess demographics, behavioral risk factors, neurocognitive function, and immune responses, as well as track sexual contacts for voluntary HIV counseling and testing. Participants will undergo regular follow-ups and blood testing to monitor their health and the progression of the infection. The findings will contribute to understanding HIV-1 immunopathogenesis and support future vaccine development.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \>18 years old
2. Have protocol-defined acute HIV-1 infection (Tested 4th generation HIV EIA negative and NAT positive or tested 4th generation HIV EIA positive, negative by less sensitive EIA and NAT positive)
3. Understand the study and sign informed consent form. Persons who cannot read will have the consent form read to them by a study staff and they can give informed consent by using thumb print.
4. Availability for follow-up for the planned study duration

Exclusion Criteria:

1. Persons who have a history of a medical or psychiatric disorder by investigator's interview and physical examination according to standard practices, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
2. Female participants who are pregnant at the time of screening

Where it's running

• Institute of HIV Research and Innovation (IHRI)
  Bangkok, Bangkok, Thailand Recruiting

Study contacts

• Study coordinator: Nittaya Phanuphak, MD, PhD
• Email: Nittaya.p@ihri.org
• Phone: 6621605371

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining immune-enhancing antibodies and vaccines to control HIV after early infection

  This test will see if giving long-acting HIV antibodies together with therapeutic vaccines helps people who began ART during acute HIV infection control viral levels after a planned treatment interruption.

  Recruiting Phase 1 Henry M. Jackson Foundation for the Advancement of Military Medicine · Pathum Wan, Bangkok · NCT06484335

• Cohort study on acute HIV infection and treatment outcomes

  This study is testing how starting HIV treatment right after diagnosis affects the chances of long-term remission in patients and what factors might help achieve that.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT05728996

• Combination broadly neutralizing HIV antibodies given with ART during acute infection to try to induce remission

  This trial will try giving two HIV-specific broadly neutralizing antibodies along with starting ART to ART-naïve adults with acute HIV infection to see if it delays viral rebound and reduces the viral reservoir.

  Recruiting at 11 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 11 other locations · NCT05719441

• Comparing standard and intensive HIV treatment for early infection

  This study is testing whether a standard HIV treatment or a stronger version works better for people who have just been diagnosed with HIV.

  Recruiting Phase 3 SEARCH Research Foundation · Bangkok · NCT00796263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.